And just this month, the federal Food and Drug Administration requested Endo Pharmaceuticals, an international pharmaceutical manufacturer, remove Opana ER —
a semi-synthetic opioid painkiller — from the market after concluding the drug's potential for abuse outweighed its therapeutic value.